Table 3 Performance of CO-RADS
First author [reference] | Country | Inclusion period [in 2020] | No. of patient | RT-PCR positivity (%) | CO-RADS 5 | ≥ CO-RADS 4 | ≥ CO-RADS 3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sen | Spe | PPV | NPV | Sen (%) | Spe (%) | PPV (%) | NPV (%) | Sen | Spe | PPV | NPV | |||||
de Jaegere [68] | Netherlands | 3/12–3/23 | 96 | 47 | 62% | 98% | 96% | 75% | 84 | 92 | 91 | 87 | – | – | – | – |
Hermans [69] | Netherlands | 3/27–4/20 | 319 | 42 | 75% | 94% | 90% | 84% | 90 | 88 | 85 | 93 | 93% | 66% | 66% | 93% |
De Smet [70] | Belgium | 3/19–4/20 | 859 | 42 | 78% | 93% | 89% | 86% | 85 | 85 | 80 | 89 | 89% | 85% | 69% | 90% |
Fujioka [71] | Japan | Jan-Jun | 154 | 49 | 53% | 94% | 90% | 67% | 68 | 88 | 85 | 74 | – | – | – | – |
Korevaar [72] | Netherlands | 3/16–4/16 | 239 | 47 | – | – | — | – | 93 | 70 | 73 | 92 | 97% | 51% | 64% | 96% |
Bellini [73] | Italy | 3/9–5/3 | 572 | 23 | – | – | – | – | 61 | 81 | 50 | 87 | – | – | – | – |
Tucato [74] | Italy | Unspecified | 120 | 43 | 91% | 91% | 92% | 90% | 75 | 75 | 77 | 72 | 74% | 76% | 77% | 72% |
Nivet [75] | France | 3/13–4/14 | 513 | 48 | 79% | 97% | 96% | 84% | 92 | 84 | 84 | 92 | 96% | 43% | 60% | 92% |
Inui [49] | Japan | 1/30–6/30 | 100 | 50 | 65% | 89% | 86% | 72% | 86 | 68 | 73 | 83 | 91% | 54% | 66% | 86% |
Lieveld [76] | Neherlands | 3/19–3/28 | 741 | 50 | – | – | – | – | 89 | 87 | 76 | 95 | 95% | 54% | 49% | 96% |
Schalekamp [77] | Netherlands | 3/20–4/3 | 1070 | 50 | 71% | 88% | 86% | 75% | 86 | 81 | 82 | 85 | 92% | 66% | 73% | 89% |
Gross [78] | Germany | 3/22–4/7 | 96 | 20 | 80% | 99% | 95% | 95% | 90 | 91 | 71 | 97 | 90% | 63% | 38% | 96% |